<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870441</url>
  </required_header>
  <id_info>
    <org_study_id>15L-CL-019</org_study_id>
    <nct_id>NCT00870441</nct_id>
  </id_info>
  <brief_title>Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Multiple Dose, Multi-Center Study to Compare the Safety of ASP2151 to Valacylcovir and Placebo in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the safety of ASP2151 to valacyclovir and placebo in
      healthy male and female adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to treatment-emergent serious adverse events
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of clinical laboratory evaluations and adverse events</measure>
    <time_frame>Days 1,4,7,10,14,17,21,24, 28 and follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of ECG, vital signs and physical examination</measure>
    <time_frame>Days 1,4,7,10,14,17,21,24 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">442</enrollment>
  <condition>Safety of ASP2151</condition>
  <arm_group>
    <arm_group_label>1. ASP2151</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <description>Oral</description>
    <arm_group_label>1. ASP2151</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Oral</description>
    <arm_group_label>2. Valacyclovir</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>3. Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject weighing at least 45 kg with a Body Mass Index (BMI) of 18-35 kg/m2,
             inclusive

          -  If female, subject is using a medically acceptable contraceptive method along with a
             double-barrier method to prevent pregnancy and agrees to continue using this method
             throughout study; and is not lactating or pregnant as documented by a negative serum
             pregnancy test

          -  The subject is medically healthy, with a normal 12-lead electrocardiogram (ECG)

        Exclusion Criteria:

          -  History of any clinically significant disease or malignancy excluding non-melanoma
             skin cancer

          -  History of liver disease, liver dysfunction, liver enzyme elevations, or Gilbert's
             disease

          -  History of acute or chronic pancreatitis or pancreatic insufficiency

          -  History of gout, hyperuricemia, or crystalluria

          -  History of chronic pain requiring medical therapy

          -  Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen
             (HBsAg)

          -  Positive test for human immunodeficiency virus (HIV) antibody

          -  Clinical laboratory tests outside the normal limits and considered by the investigator
             to be clinically significant

          -  The subject has difficulty swallowing tablets

          -  Clinically significant illness within one month prior to study drug administration

          -  History of drug or alcohol abuse within 2 years prior to study drug administration

          -  Treatment with prescription medication (with the exception of contraceptives and
             hormone replacement therapy (HRT)) or complementary and alternative medicines (CAM)
             within 14 days; over-the-counter products with exception of ibuprofen within 14 days;
             or alcohol, grapefruit or grapefruit juice containing beverage within 72 hours

          -  Donated blood or has had significant blood loss within 56 days prior to study drug
             administration or has donated plasma within 7 days prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=411</url>
    <description>Link to results on JAPIC</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP2151</keyword>
  <keyword>Valacyclovir</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

